Aug 09,2022

Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Wells Fargo downgraded Tandem Diabetes Care as competitors apply pressure to the automated insulin delivery technology developer. According to SeekingAlpha, analysts led by Larry Biegelsen moved Tandem from “Overweight” to “Underweight” due to bullish expectations on Wall Street as the company’s competition, including Insulet and Medtronic, come to the fore. The street responded in kind, with shares of TNDM down 6.8% at $56 per share in early-morning trading today.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2022

Senseonics stock is up as it sticks by revenue guidance

Senseonics shares were up after hours today on second-quarter results that came up shy of the consensus forecast. The Germantown, Maryland-based continuous glucose monitoring technology developer posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain from losses of more than $180 million this time last year on sales growth of 12.9%.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2022

Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2022

View Analyst & Ambassador Comments
Go to original news
Aug 10,2022

NuraLogix Researchers Announce AI Models that can Predict Metabolic Risks

Researchers at NuraLogix, a global leader in HealthTech AI, announced that they have developed AI models that can predict a person’s risk of Type 2 Diabetes, Hypercholesterolemia, Hypertriglyceridemia and Hypertension. This is important because it will someday allow people to screen themselves using any device with a video camera such as a smartphone or tablet.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Aug 11,2022

DarioHealth Selected by National Health Plan to Enhance Mental Health and Well-Being for Members

DarioHealth Corp., a leader in the global digital therapeutics (DTx) market, announced today that a national health plan (the "Plan"), selected Dario's behavioral health solution to drive self-service across its mental wellbeing care resources. Dario's solution will become part of the Plan's behavioral health platform to increase access to digital navigation, digital self-help and coaching.

View Analyst & Ambassador Comments
Go to original news
Aug 12,2022

Abbott will spend $450M to up FreeStyle Libre production in Ireland

Abbott will spend €440 million ($450 million) to expand its operations in Ireland, the country’s government announced today.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 14,2022

ROKIT Healthcare to Enable Innovation in Treatment of Diabetes Foot and Osteoarthritis Combining AI and 3D Bioprinting on Google Cloud

ROKIT Healthcare, a company specializing in bio-healthcare, announced it will provide a hyper-personalized medical platform that uses 3D bioprinting and AI technology built on Google Cloud, to innovate the treatment of osteoarthritis and diabetes feet (diabetic foot lesion ulcer). ROKIT Healthcare’s AI solution accurately recognizes the affected area of the patient, using computer vision and deep-learning technology, and then outputs a patch with the same size and shape as the affected area to a 3D printer. The goal for this platform is to increase the treatment rate for chronic and complex diseases, improve access to medically underprivileged areas, and lower medical expenses.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Aug 15,2022

DarioHealth Reports Second Quarter 2022 Financial and Operating Results

DarioHealth Corp., a leader in the global digital therapeutics (DTx) market, today reported financial results for the second quarter 2022 and provided a corporate and commercial update.

View Analyst & Ambassador Comments
Go to original news
Aug 15,2022

Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending June 30, 2022 and provides a business update.

View Analyst & Ambassador Comments
Go to original news
Aug 16,2022

Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes

The aim of this clinical study is to determine the feasibility, safety, and preliminary effectiveness of the Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system in pediatric subjects with type 1 diabetes in an ambulatory semi-supervised environment over a short duration of 3 days and 2 nights, or up to 60 hours.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES